Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHMSA Skyrizi IV Coverage Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentHawaii Medical Service Association (HMSA)Policy N/A

    Skyrizi IV (risankizumab-rzaa) Coverage

    Customize your policy alerts

    Sign up for all Hawaii Medical Service Association (HMSA) policy alerts

    Know when Hawaii Medical Service Association (HMSA) releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs HMSA Medicare Advantage coverage and prior authorization for physician-administered Skyrizi IV used for moderately to severely active Crohn's disease or ulcerative colitis in adults. It excludes indications where Skyrizi is usually self-administered and directs Part D members to seek coverage through their Medicare Part D plan.

    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicySkyrizi IV (risankizumab-rzaa) Coverage
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 1, 2026
    Next Review DateN/A
    Key ActionObtain precertification for Skyrizi IV before treatment.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Covered adult indications
    12 monthsCrohn's authorization
    12 monthsUlcerative colitis authorization
    RequiredAuthorization requirement

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2
    Excluded self-administered indications

    Covered Indications and Plan Rules

    Crohn's Disease

    Authorization of 12 months may be granted when the following criteria are met.

    Crohn's disease coverage criteria: The member is an adult with moderately to severely active Crohn's disease, and Skyrizi IV is requested for treatment of that condition.Moderately to severely active disease

    Authorization duration is 12 months.

    Ulcerative Colitis

    Authorization of 12 months may be granted when the following criteria are met.

    Ulcerative colitis coverage criteria: The member is an adult with moderately to severely active ulcerative colitis, and Skyrizi IV is requested for treatment of that condition.Moderately to severely active disease

    Authorization duration is 12 months.

    Requests for drugs on the applicable self-administered drug list are not covered under this policy. Skyrizi uses for moderate to severe plaque psoriasis and active psoriatic arthritis are excluded because the drug is usually self-administered for these indications.

    Members enrolled in Medicare Part D may seek coverage for Skyrizi under their Medicare Part D plan rather than under this policy.

    Initial Authorization Requirements

    Crohn's Disease

    Initial authorization may be granted for 12 months.

    Initial Crohn's disease therapy: Treatment is for moderately to severely active Crohn's disease.Moderately to severely active Crohn's disease

    Adult indication; precertification is required.

    Ulcerative Colitis

    Initial authorization may be granted for 12 months.

    Initial ulcerative colitis therapy: Treatment is for moderately to severely active ulcerative colitis.Moderately to severely active ulcerative colitis

    Adult indication; precertification is required.

    Authorization and Submission Guidance

    Prior Authorization

    Precertification is required

    Precertification is required for Skyrizi IV. Coverage is subject to the applicable approval criteria, member exclusions, dosing limits, and benefit provisions.

    Documentation Required

    Submit the specialty drug precertification form

    For precertification, refer to the HMSA medical specialty drug policy website for the required fax form.

    Denial Risk

    Self-administered uses are excluded

    Administration and Policy Scope

    Billing Rule

    Confirm the site of care

    This policy applies to drugs that are not usually self-administered and are furnished incident to a physician's service. Ensure Skyrizi IV is provided in the applicable physician-service setting.

    Terminology

    Crohn's Disease
    TermCrohn's disease (CD)
    IndicationTreatment of moderately to severely active Crohn's disease
    PopulationAdults
    Ulcerative Colitis
    TermUlcerative colitis (UC)
    IndicationTreatment of moderately to severely active ulcerative colitis
    PopulationAdults

    Policy Background

    This policy addresses coverage of Skyrizi IV (risankizumab-rzaa) when furnished incident to a physician's service and not usually self-administered. Covered adult indications include moderately to severely active Crohn's disease and moderately to severely active ulcerative colitis, provided the applicable approval criteria are met and no member or benefit exclusions apply.

    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicySkyrizi IV (risankizumab-rzaa) Coverage
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 1, 2026
    Next Review DateN/A
    Key ActionObtain precertification for Skyrizi IV before treatment.
    SourceLink
    On This Page
    Covered Indications and Plan RulesInitial Authorization RequirementsAuthorization and Submission GuidanceAdministration and Policy ScopeTerminologyPolicy Background

    Coverage may be denied when Skyrizi is requested for plaque psoriasis or psoriatic arthritis because the drug is usually self-administered for these indications and is not covered under this policy. Requests for drugs on the applicable self-administered drug list are not covered.

    Plaque Psoriasis
    TermPlaque psoriasis (PsO)
    Disease severityModerate to severe
    Eligible populationAdults who are candidates for phototherapy or systemic therapy
    Psoriatic Arthritis
    TermPsoriatic arthritis (PsA)
    Disease statusActive psoriatic arthritis
    PopulationAdults